Bacillus subtilis 3 Strain for Respiratory Pathogen Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack effective and safe probiotic bacterial strains for controlling pathogenic microorganisms in respiratory tract infections, particularly for upper and lower respiratory tract infections, which are serious and require efficient antagonistic agents.

Innovation Solution

Identification and purification of a novel Bacillus subtilis strain (B. subtilis 3) with specific growth inhibitory effects against bacteria and fungi, characterized by high purity and safety profiles, including no lecithinase activity and gamma hemolytic activity, which can be used in various formulations for therapeutic and prophylactic applications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional probiotic strains are used for controlling pathogenic microorganisms, then some level of antagonistic activity is achieved, but the effectiveness and safety are insufficient for treating respiratory tract infections

Engineering Contradiction:

Improveeffectiveness and safetyVSAvoidpathogenic microorganism control

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and isolates a specific Bacillus subtilis strain (strain 3) from mixed microbial populations, purifying it to at least 99% purity level. This extraction of the most effective and safe strain resolves the contradiction by selecting only the optimal probiotic agent that provides both high effectiveness against pathogenic microorganisms and high safety profile, eliminating ineffective or harmful variants.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality by characterizing specific functional properties of Bacillus subtilis strain 3, including its growth inhibitory effects against specific pathogenic bacteria and fungi, absence of lecithinase activity, and gamma hemolytic activity. These localized functional characteristics ensure the strain provides targeted antagonistic activity against respiratory tract pathogens while maintaining safety, resolving the effectiveness-safety contradiction.

Inventive Principle:

Principle #3Local quality

2Productivity

If highly effective antagonistic agents are used to control pathogenic microorganisms, then pathogen control improves, but safety concerns may arise

Engineering Contradiction:

Improvepathogen control efficiencyVSAvoidsafety profile

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the parameter of probiotic strain selection by identifying and using Bacillus subtilis strain 3 with specific characteristics: at least 99% purity, specific growth inhibitory effects against pathogenic bacteria and fungi, no lecithinase activity, and gamma hemolytic activity. These parameter changes ensure the strain achieves high pathogen control efficiency while maintaining an excellent safety profile suitable for respiratory tract infection treatment.

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If purified bacterial strains are used to ensure safety, then safety improves, but the complexity of strain identification and purification increases

Engineering Contradiction:

ImprovesafetyVSAvoidstrain purification process

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-characterizing Bacillus subtilis strain 3 with defined properties (growth inhibitory effects against specific pathogens, no lecithinase activity, gamma hemolytic activity) before clinical application. This preliminary identification and purification to at least 99% purity level establishes a standardized, safe probiotic agent that can be reliably produced and applied, resolving the safety-complexity contradiction through advance strain selection and characterization.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Bacillus subtilis 3 strain effectively inhibits the growth of pathogenic bacteria and fungi, demonstrating safety and efficacy in treating respiratory tract infections, and can be formulated into aerosol dispensing devices for targeted delivery.

Implementation Method 1

Various Bacillus subtilis group strains were reported to antagonize pathogenic bacteria such as Xanthomonas, Pseudomonas and Bacillus cereus group microorganisms and molds such as Fusarium, Botrytis cinerea, Phoma tracheiphila. Several bioactive components such as enzymes that degrade fungal structural polymers (protease and chitinase), lipopeptides (iturin, surfactin and fengycin), antibiotics (fengycin, surfactin, iturin and bacillomycin D) and antifungal volatiles have been identified as the main component of antagonistic mode of action

Methodology Applied

Scientific EffectAntibacterial and antifungal activity:

Implementation Method 2

The composition can be used in various formulations for therapeutic and prophylactic applications and formulated into aerosol dispensing devices for targeted delivery

Methodology Applied

Scientific EffectAerosol generation: Aerosol

Data Source

PatentUS11384333B2Compositions comprising bacterial strains and use thereof in controlling pathogenic microorganisms

Publication Date: 2022.07.12 ECOLOGICAL BALANCING TECH CORP

AI summary

An isolated bacterial strain Bacillus subtilis 3 or a functional homolog of same is provided. A sample has been deposited as KCTC 13467BP at the Korean Collection for Type Cultures, wherein the isolated microbial strain is purified to a level of at least 99%. Also provided are methods of using the isolated bacterial strain or the functional homolog of same.